Understanding Peptide Half-Life
Half-life is the time required for half of an administered compound to be eliminated or metabolized from a biological system. For research peptides, half-life determines dosing frequency, protocol design, and the practical logistics of compound administration in research settings.
Most unmodified peptides have short half-lives — often minutes — due to rapid enzymatic degradation by proteases in biological systems. This is why pharmaceutical peptide development has increasingly focused on modifications that extend half-life: PEGylation, fatty acid conjugation, D-amino acid substitution, and cyclization.
Complete Peptide Half-Life Reference Chart
| Peptide | Half-Life | Category | Route Studied | Key Modification |
|---|---|---|---|---|
| BPC-157 | ~4 hours (estimated) | Healing & Recovery | SC, Oral | Inherent gastric acid stability |
| TB-500 | ~4-6 hours | Healing & Recovery | SC | Fragment of Thymosin Beta-4 |
| KPV | ~20-30 minutes | Healing & Recovery | SC, Topical | Tripeptide (rapid clearance) |
| GHK-Cu | ~30-60 minutes | Anti-Aging & Skin | SC, Topical | Copper chelation |
| Epithalon | ~30 minutes | Anti-Aging & Skin | SC | Tetrapeptide |
| CJC-1295 (no DAC) | ~30 minutes | Growth & Performance | SC | Modified GHRH analog |
| CJC-1295 (with DAC) | ~6-8 days | Growth & Performance | SC | Drug Affinity Complex (albumin binding) |
| Ipamorelin | ~2 hours | Growth & Performance | SC | Pentapeptide GHRP |
| Sermorelin | ~10-20 minutes | Growth & Performance | SC | GHRH(1-29) fragment |
| GHRP-6 | ~20-30 minutes | Growth & Performance | SC | Hexapeptide |
| GHRP-2 | ~25-30 minutes | Growth & Performance | SC | Hexapeptide |
| Hexarelin | ~1 hour | Growth & Performance | SC | Modified hexapeptide |
| Tesamorelin | ~26-38 minutes | Growth & Performance | SC | trans-3-hexenoic acid modification |
| Semaglutide | ~7 days | Weight Management | SC | C-18 fatty acid + mini-PEG linker |
| Tirzepatide | ~5 days | Weight Management | SC | C-20 fatty acid |
| AOD-9604 | ~30-60 minutes | Weight Management | SC | hGH fragment (176-191) |
| Semax | ~2-3 minutes (serum) | Cognitive | Intranasal | ACTH(4-10) analog with Pro-Gly-Pro |
| Selank | ~2-3 minutes (serum) | Cognitive | Intranasal | Tuftsin analog with Pro-Gly-Pro |
| Dihexa | ~30 minutes (estimated) | Cognitive | SC, Oral | Modified hexapeptide |
| MOTS-C | ~4-6 hours (estimated) | Longevity | SC | Mitochondria-derived 16-aa peptide |
| SS-31 (Elamipretide) | ~4 hours | Longevity | SC | Tetrapeptide (Szeto-Schiller) |
| PT-141 (Bremelanotide) | ~2.7 hours | Other | SC | Cyclic heptapeptide |
| Oxytocin | ~3-5 minutes | Other | IV, Intranasal | Cyclic nonapeptide |
| Melanotan II | ~30-60 minutes | Other | SC | Cyclic heptapeptide |
Note: Half-life values are approximate and derived from published research. Actual values may vary based on species, dose, route of administration, and individual biological factors. Many research peptide half-lives have been estimated from animal models rather than human pharmacokinetic studies.
How Modifications Extend Half-Life
Fatty Acid Conjugation
Attaching a fatty acid chain allows the peptide to bind reversibly to serum albumin, creating a circulating reservoir that slowly releases active peptide. This is how semaglutide achieves its ~7-day half-life from a peptide that would otherwise last minutes.
Drug Affinity Complex (DAC)
The DAC modification on CJC-1295 creates a covalent bond with circulating albumin, extending the half-life from ~30 minutes to ~6-8 days. This is the most dramatic half-life extension in the GH secretagogue class.
Cyclization
Forming a ring structure within the peptide chain increases resistance to exopeptidases (enzymes that cleave from the ends). PT-141 and Melanotan II use this approach.
D-Amino Acid Substitution
Replacing L-amino acids with their D-form mirror images at specific positions makes the peptide bond resistant to protease recognition, extending half-life.
PEGylation
Attaching polyethylene glycol (PEG) chains increases molecular size (reducing renal clearance) and creates a steric shield against protease access.
Half-Life and Protocol Design
Half-life directly determines how frequently a compound must be administered to maintain consistent research concentrations:
- Short half-life (<1 hour): Requires frequent administration. Semax and Selank are administered 2-3 times daily in published research protocols.
- Medium half-life (1-6 hours): Once or twice daily administration. BPC-157, Ipamorelin, and TB-500 typically fall in this range.
- Long half-life (days): Weekly or less frequent administration. Semaglutide (weekly) and CJC-1295 DAC (weekly to bi-weekly) benefit from modifications that dramatically extend their presence in the system.
Steady-State Considerations
With repeated dosing, peptide levels accumulate until reaching steady state — typically after 4-5 half-lives. For semaglutide with a 7-day half-life, steady state is reached at approximately 4-5 weeks of weekly dosing. For short-half-life peptides, steady state is reached within hours of establishing a regular dosing schedule.
Why This Matters for Subscriptions
Half-life data directly informs how quickly researchers consume their peptide supply:
- Short half-life peptides requiring daily administration deplete vials faster → 30-day subscription interval recommended
- Long half-life peptides with weekly dosing last longer → 60 or 90-day subscription interval may be appropriate
BeaCapra's subscription model lets you match your delivery frequency to your actual consumption rate — choose 30, 60, or 90-day intervals, and adjust as your protocol evolves.
Frequently Asked Questions
What does half-life mean for peptides?
Half-life is the time it takes for half of the administered peptide to be eliminated or metabolized from the system. A peptide with a 2-hour half-life has half remaining after 2 hours, one-quarter after 4 hours, one-eighth after 6 hours, and is effectively cleared after 5 half-lives (~10 hours).
Why do some peptides have much longer half-lives?
Chemical modifications such as fatty acid conjugation (semaglutide), Drug Affinity Complex (CJC-1295 DAC), or cyclization (PT-141) protect peptides from enzymatic degradation and reduce renal clearance, dramatically extending their half-life from minutes to days.
Does route of administration affect half-life?
Yes. Subcutaneous injection typically provides the longest effective half-life due to slow absorption from the injection site. Intravenous administration delivers the full dose immediately but also subjects it to immediate clearance. Intranasal and oral routes have their own absorption and metabolism profiles.
How does half-life affect dosing frequency?
Shorter half-life = more frequent dosing. A compound with a 2-hour half-life needs 1-3 daily administrations to maintain research concentrations. A compound with a 7-day half-life needs only weekly dosing.
Are half-life values exact?
No. Published half-life values are averages from specific research conditions (species, dose, route). Individual variation, concurrent compounds, and metabolic factors all influence actual clearance rates. Use published values as guidelines, not absolute numbers.